197 related articles for article (PubMed ID: 17948601)
21. Ribavirin in chronic hepatitis C: past and future.
Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
[No Abstract] [Full Text] [Related]
22. Treatment of chronic hepatitis C in southern Taiwan.
Chuang WL; Yu ML; Dai CY; Chang WY
Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
[TBL] [Abstract][Full Text] [Related]
23. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
Yu ML; Dai CY; Lee LP; Hsieh MY; Hou NJ; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Antivir Ther; 2006; 11(8):1015-9. PubMed ID: 17302371
[TBL] [Abstract][Full Text] [Related]
24. PegIFN/ribavirin during acute HCV coinfection.
Bernard EJ
IAPAC Mon; 2004 Jul; 10(7):260-1. PubMed ID: 15624247
[No Abstract] [Full Text] [Related]
25. Hepatitis C: CIFN for re-treatment of PEG-IFN plus RBV nonresponders?
Trepo C; Pradat P
Nat Rev Gastroenterol Hepatol; 2009 Oct; 6(10):570-1. PubMed ID: 19789573
[No Abstract] [Full Text] [Related]
26. Impact of occult hepatitis B virus infection or hepatitis B virus DNA integration on efficacy of chronic hepatitis C treatment with peginterferon and ribavirin: where are we?
Hu KQ; Zhang YY
J Clin Gastroenterol; 2014 Jan; 48(1):3-5. PubMed ID: 24045272
[No Abstract] [Full Text] [Related]
27. Use of PEG-interferon alfa-2a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL.
Lo Nigro L; La Spina M; Mirabile E; Pisana P; Schilirò G; Guardo P
Pediatr Blood Cancer; 2004 Aug; 43(2):185. PubMed ID: 15236293
[No Abstract] [Full Text] [Related]
28. [Treatment of chronic hepatitis C: shorter treatment duration for genotype 2 or 3 infection].
Jeong SH
Korean J Hepatol; 2007 Sep; 13(3):301-3. PubMed ID: 17898546
[No Abstract] [Full Text] [Related]
29. [Management of sarcoidosis-associated chronic hepatitis C virus infection: course and treatment].
Longueira Suárez R; Ammari I; Lamas Ferreiro JL; Sopeña Pérez-Argüelles B; Martínez-Vázquez C
Rev Clin Esp; 2009; 209(7):358-9. PubMed ID: 19709544
[No Abstract] [Full Text] [Related]
30. Tolerability of Peg interferon-alpha2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency.
Demelia L; Civolani A; Murgia D; Murru A; Sorbello O; Rizzetto M
J Hepatol; 2007 Jan; 46(1):171-3. PubMed ID: 17107736
[No Abstract] [Full Text] [Related]
31. [Treatment of chronic hepatitis C with pegylated alpha-interferons].
Niederau C
Dtsch Med Wochenschr; 2002 Mar; 127(11):563-6. PubMed ID: 11894177
[No Abstract] [Full Text] [Related]
32. Successful desensitization to ribavirin in a patient with chronic hepatitis C.
Ladd AM; Martel-Laferriere V; Dieterich D
J Clin Gastroenterol; 2012 Sep; 46(8):716-7. PubMed ID: 22739224
[No Abstract] [Full Text] [Related]
33. Treatment of chronic hepatitis C in haemodialysis patients requires more ribavirin.
Slavenburg S; Drenth JP
Nephrol Dial Transplant; 2008 Jul; 23(7):2430; author reply 2430-1. PubMed ID: 18400821
[No Abstract] [Full Text] [Related]
34. [Type 1 diabetes developing during alpha-interferon therapy: report of two cases].
Vinagre I; Rigla M; Torras X; Enríquez J; Corcoy R
Endocrinol Nutr; 2010 Oct; 57(8):393-5. PubMed ID: 20462813
[No Abstract] [Full Text] [Related]
35. Pegylated interferon (PEG-Intron) for chronic hepatitis C.
Med Lett Drugs Ther; 2001 Jun; 43(1107):54-5. PubMed ID: 11426190
[No Abstract] [Full Text] [Related]
36. [Interferons alpha in the treatment of chronic HCV infections].
Halota W; Pawłowska M; Andrejczyn M
Przegl Epidemiol; 2004; 58(3):405-11. PubMed ID: 15730004
[TBL] [Abstract][Full Text] [Related]
37. HCV therapy with daclatasvir, PEG-IFN, and RBV after boceprevir-based therapy failure post-liver transplantation in hyper-IgM syndrome.
Reddy KR; Wirjosemito A; Pavri TM; Sinese L
Transplantation; 2014 Apr; 97(8):e47-8. PubMed ID: 24732900
[No Abstract] [Full Text] [Related]
38. [Possible telaprevir-induced pancreatitis. A case study].
Selvi Sabater P; Espuny Miró A; Muñoz Bertrán ED; Plaza Aniorte J
Farm Hosp; 2013; 37(3):269-70. PubMed ID: 23789806
[No Abstract] [Full Text] [Related]
39. [Diabetes mellitus during interferon therapy].
Tarabini-Castellani P; Apraiz L; Portu J; Agud JM
Enferm Infecc Microbiol Clin; 2008 Feb; 26(2):120-1. PubMed ID: 18341927
[No Abstract] [Full Text] [Related]
40. [PEG-interferons: significance for the treatment of viral hepatitis B and C].
Wedemeyer H; Cornberg M; Manns MP
Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S68-75. PubMed ID: 11450618
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
